Skandinaviska Enskilda Banken AB publ Has $167.77 Million Position in Bristol Myers Squibb Company $BMY

Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 59.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,719,987 shares of the biopharmaceutical company’s stock after buying an additional 1,393,646 shares during the period. Bristol Myers Squibb makes up about 0.7% of Skandinaviska Enskilda Banken AB publ’s holdings, making the stock its 24th biggest position. Skandinaviska Enskilda Banken AB publ owned approximately 0.18% of Bristol Myers Squibb worth $167,771,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Gateway Investment Advisers LLC lifted its stake in shares of Bristol Myers Squibb by 10.0% in the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after buying an additional 10,284 shares during the last quarter. CWA Asset Management Group LLC lifted its position in Bristol Myers Squibb by 25.9% during the 3rd quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock worth $6,781,000 after acquiring an additional 30,909 shares during the last quarter. Commonwealth Retirement Investments LLC boosted its holdings in Bristol Myers Squibb by 24.6% during the second quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock valued at $2,740,000 after acquiring an additional 11,690 shares during the period. Stephens Inc. AR grew its position in shares of Bristol Myers Squibb by 13.5% in the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock valued at $12,328,000 after purchasing an additional 32,476 shares during the last quarter. Finally, Railway Pension Investments Ltd increased its stake in shares of Bristol Myers Squibb by 3.7% in the third quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock worth $51,396,000 after purchasing an additional 40,300 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on BMY shares. The Goldman Sachs Group reiterated a “neutral” rating and set a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price target for the company from $52.00 to $61.00 in a report on Monday, December 15th. Guggenheim restated a “buy” rating and set a $72.00 price objective (up previously from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Truist Financial set a $65.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, December 3rd. Finally, HSBC restated a “hold” rating and set a $53.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Eight analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $59.20.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $60.64 on Tuesday. The firm has a market capitalization of $123.49 billion, a PE ratio of 17.58, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The firm has a 50-day moving average price of $55.50 and a 200 day moving average price of $49.61.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same period in the previous year, the firm posted $1.67 earnings per share. The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were given a dividend of $0.63 per share. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.